MPN

Researchers are identifying targets to treat chronic lymphocytic leukemia.

Injured DNA can hide damaged blood cells in myelodysplastic syndrome (MDS).

The FDA has approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML).

A novel agent is attacking a newly found target in patients with acute myeloid leukemia (AML).

Chemo fog, or chemo brain, is a very real phenomena that cancer survivors need to be knowledgeable about. This describes the journey of one survivor.

Bosulif (bosutinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) for use in the first-line treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).

End-of-life care is of particular concern for elderly patients with AML because prognosis is poor and has not changed in several decades. Median survival for patients 65 or older is roughly two months and drops to as low as one month for patients over 85 years.

CURE spoke with Rami S. Komrokji, M.D. about collaborative efforts that will lead to new advances in the treatment of myelodysplastic syndrome (MDS).

A recent study found that gender makes a difference in the survival of a patient with ET.

Eunice Wang, M.D., discusses a promising new drug for the treatment of certain patients with acute myeloid leukemia.

It's time to start paying attention to what comes after cancer treatment.

Kendra Sweet, M.D., discussed the various factors that must be taken into account when prescribing first-line therapies to patients with CML, the novel studies that are paving the way for improved outcomes in patients, and the increasing likelihood for TKI discontinuation on the horizon.

Can a drug used to treat arthritis also be a way to treat polycythemia vera (PV), and save patients with the blood cancer money?

MPN treatment and diagnostic strategies have come a long way in recent years, but still have a ways to go.

Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.

In an interview with CURE, Rami Komrokji, M.D., a hematologist at Moffitt Cancer Center in Tampa, Florida, discusses the advances that have been made in MDS in the past few years, as well as the MDS Clinical Research Consortium and its importance.

MDS is a rare form of cancer with its own unique characteristics. Here is one patients perspective on the experience of having MDS.

Patients with MPNs face unique challenges with depression and sexual intimacy. Sandra Allen-Bard, BSN, MSN, AOCNP, ANCC, discusses a recent study conducted to better understand these issues.

Rami S. Komrokji, M.D., clinical director of Hematologic Malignancies at Moffitt Cancer Center, discusses an unmet need in the treatment of myelodysplastic syndrome (MDS).

ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.

Clinical trial enrollment is vital for the field of MPN treatment to continue to progress forward.

While clinical trials are paving the way for new treatments to treat hematologic malignancies, but many patients are apprehensive to participate in them after considering the costs.

An ongoing trial is seeking to find out if a patient with an MPN can improve their health status through nutritional interventions.

After publishing them in October 2016,the National Comprehensive Cancer Network (NCCN) is already seeking to update and expand their guidelines for diagnosing and treating patients with myeloproliferative neoplasms (MPNs).

Finola Hughes from TV's "General Hospital" and Ellen K. Ritchie, M.D. are teaming up to raise awareness for polycythemia vera.

Andrew Schorr, founder of Patient Power and Patient Empowerment and 2016 MPN Hero, discusses how his background in journalism led him to patient advocacy.

Ross L. Levine, M.D., physician-scientist, director of the Memorial Sloan Kettering (MSK) Center for Hematologic Malignancies and 2016 MPN Hero, discusses the work at his lab that he is currently excited about.